›Portfolio Companies

Past, Present and Future Leaders

The managing directors of IWHP are proud and privileged to have partnered with visionary management teams who are shaping the future of Biotech, Medical Devices and Healthcare IT. The groundbreaking businesses they have created are representative of the industry-leading companies that InterWest has helped build over the last three decades.

Our Companies

VENTURE INVESTING IN BREAKTHROUGH HEALTHCARE COMPANIES

Doug Fisher

dougfisher

Partner

InterWest Team

Current Investments

Prior Investments

Doug's bio

Portfolio
Company News

Doug's
Perspective

Doug's Buzz

Doug's video

Doug joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. He is a board member of Gynesonics, Indi MolecularObalon Therapeutics (OBLN)and QuatRx. Doug is also actively involved in InterWest's investments in BenvenueIntegrated Diagnostics, PMV PharmaPotenza Theraputics, and Sera Prognostics (where he serves as the Chief Business Officer).

Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group.

Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford, where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar.

 

Doug Fisher